Gerber Kawasaki Wealth & Investment Management decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,125 shares of the company’s stock after selling 305 shares during the quarter. Gerber Kawasaki Wealth & Investment Management’s holdings in IDEXX Laboratories were worth $209,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in IDEXX Laboratories by 0.3% during the third quarter. Vanguard Group Inc. now owns 8,918,451 shares of the company’s stock worth $2,226,581,000 after acquiring an additional 23,970 shares during the period. Vanguard Group Inc increased its position in IDEXX Laboratories by 0.3% during the third quarter. Vanguard Group Inc now owns 8,918,451 shares of the company’s stock worth $2,226,581,000 after acquiring an additional 23,970 shares during the period. Capital World Investors increased its position in IDEXX Laboratories by 0.3% during the third quarter. Capital World Investors now owns 1,072,475 shares of the company’s stock worth $267,754,000 after acquiring an additional 3,693 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd increased its position in IDEXX Laboratories by 4.4% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 943,305 shares of the company’s stock worth $175,473,000 after acquiring an additional 40,046 shares during the period. Finally, Federated Investors Inc. PA increased its position in IDEXX Laboratories by 16.9% during the third quarter. Federated Investors Inc. PA now owns 588,433 shares of the company’s stock worth $146,908,000 after acquiring an additional 85,257 shares during the period. 92.45% of the stock is currently owned by hedge funds and other institutional investors.
IDEXX Laboratories stock traded up $5.34 during trading hours on Friday, reaching $216.21. 940,708 shares of the stock were exchanged, compared to its average volume of 547,071. IDEXX Laboratories, Inc. has a twelve month low of $176.11 and a twelve month high of $256.22. The company has a market capitalization of $18.28 billion, a price-to-earnings ratio of 50.75 and a beta of 0.97.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Friday, February 1st. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.08. IDEXX Laboratories had a net margin of 17.03% and a negative return on equity of 1,501.97%. The company had revenue of $549.39 million for the quarter, compared to the consensus estimate of $546.04 million. During the same period last year, the company posted $0.43 EPS. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 4.69 earnings per share for the current year.
In other news, insider Michael Lane sold 971 shares of the firm’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $208.00, for a total value of $201,968.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jonathan W. Ayers sold 15,905 shares of the firm’s stock in a transaction that occurred on Wednesday, February 6th. The shares were sold at an average price of $208.13, for a total transaction of $3,310,307.65. Following the completion of the sale, the chief executive officer now owns 1,047,226 shares in the company, valued at $217,959,147.38. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,144 shares of company stock worth $8,378,892. 2.56% of the stock is currently owned by corporate insiders.
A number of research firms recently commented on IDXX. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 price target on the stock in a research report on Monday, February 4th. BidaskClub upgraded shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a research note on Thursday, January 24th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. IDEXX Laboratories currently has an average rating of “Buy” and a consensus price target of $246.00.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
See Also: No Load Funds
Receive News & Ratings for IDEXX Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IDEXX Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.